指南与共识消化道肿瘤与早癌消化内镜

AGA临床实践更新:结直肠癌筛查与息肉切除后监测的风险分层专家评论

AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review.
指南 / 共识 · Gastroenterology · 2023-09-21

美国胃肠病学会(AGA)发布临床实践更新专家评论,提出结直肠癌筛查与息肉切除后监测的风险分层建议。该评论基于文献回顾与专家意见形成9条最佳实践建议,因未做系统评价,建议未对证据质量或推荐强度进行正式评级。

要点

  • 一级亲属确诊结直肠癌者,尤其确诊年龄小于50岁,应考虑为结直肠癌风险增高。
  • 无结直肠癌个人史、炎症性肠病、遗传性结直肠癌综合征、其他易感情况及家族史者,考虑为平均风险。
  • 平均风险者45岁开始筛查;一级亲属患结直肠癌者,筛查起始年龄为最年轻患者确诊年龄前10年或40岁,取更早者。

核心结论

  • 该专家评论描述了如何对个体进行结直肠癌筛查与息肉切除后监测的风险分层,并指出未来研究应填补现有文献空白。

研究设计与样本

  • 美国胃肠病学会(AGA)研究所临床实践更新委员会(CPUC)和AGA理事会委托并批准的专家评论,经内部同行评议和Gastroenterology标准外部同行评议,基于已发表文献回顾与专家意见形成最佳实践建议,未进行系统评价,建议未对证据质量或推荐强度进行正式评级。

主要发现

  • 自2000年代初以来,结直肠癌死亡率快速下降,很大程度上归因于筛查和癌前息肉切除;但结直肠癌仍是美国癌症死亡的第二大原因,2023年预计约53,000例死亡。

关键数值与推荐

  • 最佳实践建议1:一级亲属(父母、兄弟姐妹或子女)确诊结直肠癌者,尤其确诊年龄小于50岁,应考虑为结直肠癌风险增高。
  • 最佳实践建议2:无结直肠癌个人史、炎症性肠病、遗传性结直肠癌综合征、其他结直肠癌易感情况或结直肠癌家族史者,应考虑为平均风险。
  • 最佳实践建议3:平均风险者应在45岁开始筛查;因一级亲属患结直肠癌而风险增高者,应在最年轻受累亲属确诊年龄前10年或40岁开始筛查,取更早者。
  • 最佳实践建议4:筛查起始的风险分层应基于个体年龄、已知或怀疑的遗传性结直肠癌综合征和/或结直肠癌家族史。
  • 最佳实践建议5:75岁以上个体是否继续结直肠癌筛查应个体化,基于风险、获益、筛查史和合并症的评估。

临床怎么用

  • 最佳实践建议6:平均风险者的筛查选项应包括结肠镜、粪便免疫化学检测、软式乙状结肠镜联合粪便免疫化学检测、多靶点粪便DNA粪便免疫化学检测和计算机断层结肠成像,基于可及性和个体偏好选择。
  • 最佳实践建议7:结直肠癌风险增高者应使用结肠镜作为筛查策略。
  • 最佳实践建议8:75岁以上个体是否继续息肉切除后监测应个体化,基于风险、获益和合并症的评估。
  • 最佳实践建议9:研究中出现的结直肠癌筛查与息肉切除后监测风险分层工具,在广泛实施前应在多样化人群中(如按种族、民族、性别及与结直肠癌结局差异相关的其他社会人口学因素)检验其真实世界有效性和成本效益。

局限性

  • 因未进行系统评价,这些最佳实践建议未对证据质量或所提考虑因素的强度进行正式评级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: Since the early 2000s, there has been a rapid decline in colorectal cancer (CRC) mortality, due in large part to screening and removal of precancerous polyps. Despite these improvements, CRC remains the second leading cause of cancer deaths in the United States, with approximately 53,000 deaths projected in 2023. The aim of this American Gastroenterological Association (AGA) Clinical Practice Update Expert Review was to describe how individuals should be risk-stratified for CRC screening and post-polypectomy surveillance and to highlight opportunities for future research to fill gaps in the existing literature. METHODS: This Expert Review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Gastroenterology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: All individuals with a first-degree relative (defined as a parent, sibling, or child) who was diagnosed with CRC, particularly before the age of 50 years, should be considered at increased risk for CRC. BEST PRACTICE ADVICE 2: All individuals without a personal history of CRC, inflammatory bowel disease, hereditary CRC syndromes, other CRC predisposing conditions, or a family history of CRC should be considered at average risk for CRC. BEST PRACTICE ADVICE 3: Individuals at average risk for CRC should initiate screening at age 45 years and individuals at increased risk for CRC due to having a first-degree relative with CRC should initiate screening 10 years before the age at diagnosis of the youngest affected relative or age 40 years, whichever is earlier. BEST PRACTICE ADVICE 4: Risk stratification for initiation of CRC screening should be based on an individual's age, a known or suspected predisposing hereditary CRC syndrome, and/or a family history of CRC. BEST PRACTICE ADVICE 5: The decision to continue CRC screening in individuals older than 75 years should be individualized, based on an assessment of risks, benefits, screening history, and comorbidities. BEST PRACTICE ADVICE 6: Screening options for individuals at average risk for CRC should include colonoscopy, fecal immunochemical test, flexible sigmoidoscopy plus fecal immunochemical test, multitarget stool DNA fecal immunochemical test, and computed tomography colonography, based on availability and individual preference. BEST PRACTICE ADVICE 7: Colonoscopy should be the screening strategy used for individuals at increased CRC risk. BEST PRACTICE ADVICE 8: The decision to continue post-polypectomy surveillance for individuals older than 75 years should be individualized, based on an assessment of risks, benefits, and comorbidities. BEST PRACTICE ADVICE 9: Risk-stratification tools for CRC screening and post-polypectomy surveillance that emerge from research should be examined for real-world effectiveness and cost-effectiveness in diverse populations (eg, by race, ethnicity, sex, and other sociodemographic factors associated with disparities in CRC outcomes) before widespread implementation.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Issaka RB, Chan AT, Gupta S, et al. AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review. Gastroenterology. 2023. PMID: 37737817. doi:10.1053/j.gastro.2023.06.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。